Latest News & Features
Biotechnology
US medical device company alleges Catalyst Orthoscience infringed patent through reverse shoulder surgery system | Firm seeks to enforce a patent granted in October last year. 29 February 2024
Big Pharma
Firm wishes to avoid ‘protracted litigation’ with confidential settlement | Counsel for GSK told Delaware judge in January that lawsuits are ‘way ahead of the science’. 29 February 2024
Careers
Partner with extensive patent litigation experience joins London office | A&O is finalising merger with Shearman & Sterling. 28 February 2024
Biotechnology
UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing. 27 February 2024
Biotechnology
DePuy Synthes tries to overturn a ruling over knee replacement device | Challenges the court's decision, including ownership disputes, interpretation of critical terms, and the granting of a permanent injunction. 27 February 2024
Medtech
Australia-based spinal orthotics device company files suit against ChiroLux | Alleges infringement of one of its chiropractic products aimed at relieving neck pain. 22 February 2024
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs. 22 February 2024
Unified Patent Court
International membership organisation launches platform enabling access to UPC cases and statistics | Tool aims to provide transparency amidst concerns and latest decision requiring legal representation to request access to court documents | Life sciences cases take up two-thirds of UPC cases. 20 February 2024
Big Pharma
Board determines that Nevro added subject matter to patent through amendment | Medtronic and Boston Scientific have successfully overturned 2019 decision rejecting opposition. 20 February 2024
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter. 20 February 2024